{"name":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","slug":"beijing-dayspring-pharmaceutical-technology-co-ltd","ticker":"","exchange":"","domain":"beijingdayspringtechnology.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo foam","genericName":"Placebo foam","slug":"placebo-foam","indication":"Other","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"minoxidil + finasteride","genericName":"minoxidil + finasteride","slug":"minoxidil-finasteride","indication":"Androgenetic alopecia (male pattern baldness)","status":"marketed"}]}],"pipeline":[{"name":"Placebo foam","genericName":"Placebo foam","slug":"placebo-foam","phase":"marketed","mechanism":"Placebo foam is an inert formulation with no active pharmaceutical ingredient, serving as a control or vehicle for topical application.","indications":[],"catalyst":""},{"name":"minoxidil + finasteride","genericName":"minoxidil + finasteride","slug":"minoxidil-finasteride","phase":"marketed","mechanism":"Minoxidil stimulates hair growth by prolonging the anagen phase and improving blood flow to hair follicles, while finasteride inhibits 5-alpha reductase to reduce DHT-mediated hair loss.","indications":["Androgenetic alopecia (male pattern baldness)","Hair loss in men"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}